Literature DB >> 17054598

A longitudinal observational study of insulin therapy and glycaemic control in Scottish children with Type 1 diabetes: DIABAUD 3.

.   

Abstract

OBJECTIVE/
BACKGROUND: Our objective was to investigate glycaemic control in children with Type 1 diabetes in Scotland and to analyse the effect of changing 'conventional' insulin regimen strategies on outcome. DIABAUD 2 (1997-1998) (D2) demonstrated that average glycaemic control in young people with Type 1 diabetes in Scotland was poor, with mean HbA(1c) of 9.0%. Over 90% were then treated with a twice-daily insulin regimen. The aim of DIABAUD 3 (2002-2004) (D3) was to determine if control had improved, and to examine changes in insulin regimen and effects on glycaemic control.
METHODS: In DIABAUD 3, data were collected prospectively on children aged < 15 years. in nine out of 15 centres throughout Scotland. HbA(1c) on 986 subjects was measured in a single Diabetes Control and Complications Trial-aligned laboratory. The results were compared with those from DIABAUD 2, for the same nine centres. Multiple regression comparison was performed to adjust for imbalance in relevant confounders (e.g. age, duration, height and weight, insulin dose and centre).
RESULTS: For D3, the age range was 1.1-14.9 years (62% aged 10-14 years), mean (+/- sd) HbA(1c) 9.2% +/- 1.5 (compared with D2, 9.0% +/- 1.5). Only 9.7% achieved the target of HbA(1c) < 7.5%. The number of subjects in D3 on twice-daily injections was 51% (compared with 94% in D2), 43% on three-times-daily injections (2% in D2) and 2.3% on four or more (1.9% in D2): HbA(1c) did not differ in these groups. In both the D2 and D3 cohorts, HbA(1c) rose with age. After adjustment for other variables in the combined datasets, insulin regimen was not a significant predictor of HbA(1c) (F = 0.19, d.f. = 3, 1774; P = 0.90).
CONCLUSION: The glycaemic control in young people in Scotland remains poor and above the national target. Over 4 years, moderate intensification of insulin therapy (i.e. from two to three injections each day, usually reflecting splitting of the evening dose) across the population failed to improve the average HbA(1c) and reduce the increase seen with age. A national programme away from 'conventional' to an 'intensive' regimen of insulin therapy is required.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17054598     DOI: 10.1111/j.1464-5491.2006.01962.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  5 in total

1.  Use of an automated bolus calculator reduces fear of hypoglycemia and improves confidence in dosage accuracy in patients with type 1 diabetes mellitus treated with multiple daily insulin injections.

Authors:  Katharine Barnard; Christopher Parkin; Amanda Young; Mansoor Ashraf
Journal:  J Diabetes Sci Technol       Date:  2012-01-01

Review 2.  Fear of hypoglycaemia in parents of young children with type 1 diabetes: a systematic review.

Authors:  Katharine Barnard; Sian Thomas; Pamela Royle; Kathryn Noyes; Norman Waugh
Journal:  BMC Pediatr       Date:  2010-07-15       Impact factor: 2.125

3.  Glycemic control in children with type 1 diabetes in wales: influence of the pediatric diabetes specialist nurse.

Authors:  Malachy O'Hagan; John N Harvey
Journal:  Diabetes Care       Date:  2010-04-30       Impact factor: 19.112

4.  Improving communication and recall of information in paediatric diabetes consultations: a qualitative study of parents' experiences and views.

Authors:  Julia Lawton; Norman Waugh; Kathryn Noyes; Kathryn Barnard; Jeni Harden; Louise Bath; John Stephen; David Rankin
Journal:  BMC Pediatr       Date:  2015-06-10       Impact factor: 2.125

5.  Does an intensive self-management structured education course improve outcomes for children and young people with type 1 diabetes? The Kids In Control OF Food (KICk-OFF) cluster-randomised controlled trial protocol.

Authors:  Katherine J Price; Jerry Wales; Christine Eiser; Julie Knowles; Simon Heller; Jenny Freeman; Alan Brennan; Amy McPherson; Jerry Wellington
Journal:  BMJ Open       Date:  2013-01-24       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.